 | Up a level |
Group by: Item Type | Date
Jump to: Article | Conference or Workshop Item
Number of items: 5.
Article
- Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I. and Ramage, J. (2017) High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget. 8(60) 1949-2553.
- Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I. and Ramage, J. (2017) High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget. 8(60), pp. 101215-101223. 1949-2553.
Conference or Workshop Item
- Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 06-09 November 2016.
- Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, University of Birmingham, 2016-11-06 - 2016-11-09.
- Machado, L., Moseley, P., Moss, R., Nolan, C., Rampage, J., Chan, S. and Durrant, L. G. (2014) High-mobility group protein 1 (HMGB1) is an independent predictor of poor survival in ovarian cancer. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 02-05 November 2014. Also presented at: British Society for Immunology Annual Congress (BSI2014), Brighton, UK, 01-04 December 2014 (Unpublished)